Source comparison
Melanotan-2 vs Bremelanotide (PT-141) for Sexual Dysfunction
Melanotan-2 sexual dysfunction research led directly to the development of bremelanotide (PT-141), the only FDA-approved melanocortin agonist for sexual dysfunction. Bremelanotide is a Melanotan-2 analog with a single amino acid substitution. Norleucine replac
This comparison does not assign a generated winner or score.
- Melanotan-2 sexual dysfunction research led directly to the development of bremelanotide (PT-141), the only FDA-approved melanocortin agonist for sexual dysfunction. Bremelanotide is a Melanotan-2 analog with a single amino acid substitution. Norleucine replaced with a different residue to reduce melanocortin-1 receptor (MC1R) binding, which minimizes tanning and nausea while preserving MC4R agonism for sexual arousal.
- The FDA approved bremelanotide in June 2019 under the trade name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Defined as persistently low sexual desire causing marked distress and not attributable to medical conditions, relationship issues, or other medications. The approval was based on two Phase III trials (RECONNECT studies) involving over 1,200 women. Participants self-administered 1.75 mg subcutaneously 45 minutes before anticipated sexual activity. Compared to placebo, bremelanotide significantly increased the number of satisfying sexual events per month and reduced distress related to low desire.
- Melanotan-2 was never submitted for FDA approval for sexual dysfunction despite earlier and more extensive research. Why? The side effect profile. Melanotan-2 causes dose-dependent nausea in 40–60% of users at sexually effective doses (1–2 mg subcutaneously), along with facial flushing, increased blood pressure, and spontaneous erections lasting several hours. Acceptable in research contexts but problematic for commercial approval. Bremelanotide's structural modification reduced nausea incidence to approximately 40% (still significant but improved) and eliminated prolonged erections, making it viable for FDA review.
- The pharmacokinetic difference is also critical. Melanotan-2 has a half-life of approximately 33 minutes in plasma but persists in tissue for hours due to melanocortin receptor binding. Bremelanotide has a similar half-life (2.7 hours) but more predictable clearance, reducing the risk of multi-day effects that complicated Melanotan-2 clinical development.
- For male erectile dysfunction specifically, neither compound received FDA approval. Bremelanotide's trials focused exclusively on female HSDD, and Melanotan-2's erectile effects, while well-documented in multiple studies, never advanced past Phase II due to regulatory and commercial hurdles. Off-label use persists because the mechanism works. MC4R agonism increases erectile function in men regardless of FDA approval status. But prescribers must weigh efficacy against side effect burden and legal status.
- Researchers continue exploring melanocortin pathways. A 2021 systematic review in Sexual Medicine Reviews analyzed 18 preclinical and clinical studies on melanocortin agonists for sexual dysfunction and concluded that MC4R-selective compounds consistently improve arousal, desire, and genital response across sexes and species, but side effect mitigation remains the primary barrier to broader clinical use. The precision synthesis standards applied to compounds like PT 141 Bremelanotide ensure receptor selectivity that minimizes off-target melanocortin-1 receptor activation responsible for hyperpigmentation.